DUMAC Inc’s Flexion Therapeutics, Inc. FLXN Stock Holding History

DUMAC Inc’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-99,129	Closed	-$887K	–	41
2021 Q1	$887K	Buy	+99,129	New	+$1.14M	1.23%	12

Other funds holding FLXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DUMAC Inc's FLXN Position: Q2 2021 in Review

DUMAC Inc sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2021, closing a stake of 99,129 shares — an estimated $887K sold.

DUMAC Inc first reported a position in FLXN in Q1 2021 and held it in 1 quarter. The position peaked at $887K in Q1 2021. 140 funds tracked by Wall St. Rank hold FLXN as of Q2 2021.

DUMAC Inc reported no remaining Flexion Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
DUMAC Inc sold 99,129 Flexion Therapeutics, Inc. shares in Q2 2021, an estimated $887K.
DUMAC Inc first reported a position in Flexion Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
DUMAC Inc's Flexion Therapeutics, Inc. position peaked at $887K in Q1 2021.
140 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2021.

Based on DUMAC Inc's 13F filing for Q2 2021, filed 16 Aug 2021.